Click here to listen to the audio recording of Diabetes Health in The News.
Researchers recently compared the success rates in using once-daily Vildagliptin vs. Januvia (Sitagliptin) in treating patients living with type 2 diabetes. A study was completed using information from participants across outpatient centers in the U.S. and Brazil with type 2 diabetes that also had severe renal impairments. Researchers found that throughout the 24 weeks of treatment, participants taking either medication noticed HbA1c reductions.
This information can be extremely useful for doctors assisting patients better manage their diabetes. Both Vildagliptin and Sitagliptin demonstrated similar success in patients that had severe renal impairments. This study provides excellent support for using DPP-4 inhibitors in treating patients with severe renal impairment.
These findings were published in Diabetologia on September 2015.